PMID: 15243217Jul 10, 2004Paper

Cardiovascular outcomes among participants with diabetes in the recent large statin trials

Current Opinion in Lipidology
J Armitage, Louise Bowman

Abstract

Despite their increased cardiovascular risk and its continuous relationship with cholesterol, until recently only diabetic patients with marked dyslipidaemia were routinely offered lipid-lowering therapy. The secondary prevention statin trials led to more widespread cholesterol lowering in patients with coronary disease and diabetes. Here we review the results of recent randomized trials, which included substantial numbers of patients with diabetes and no vascular disease. The MRC/BHF Heart Protection Study included 5963 participants with diabetes, of whom 2912 had no history of vascular disease at baseline. Patients were randomized to 40 mg simvastatin daily or matching placebo for 5 years, which, on average, reduced LDL by 1.0 mmol/l compared with placebo. Highly significant reductions of about one-quarter in major vascular events were seen both overall and in different types of patient with diabetes, including those with average and below average lipid levels. Recent data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial and the Anglo-Scandinavian Cardiac Outcomes Trial support these findings and are consistent with these effects. Good quality, randomized trials including substantial number...Continue Reading

References

Jan 1, 1984·Journal of Chronic Diseases·T P SzatrowskiH Kato
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Mar 29, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·H M ColhounUNKNOWN Collaborative AtoRvastatin Diabetes Study (CARDS)
Sep 21, 2002·Lancet·Duncan M Geddes
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jun 13, 2003·Lancet·Joep Killestein
Jun 27, 2003·Lancet
Sep 6, 2003·Lancet·Cesare R Sirtori
Oct 15, 2003·Circulation·Jeffrey A Cutler, Thomas Thom
Dec 25, 2003·Diabetes Care·Steven M Haffner, UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Nov 6, 2010·Current Atherosclerosis Reports·Abhishek Deshmukh, Jawahar L Mehta
Jul 22, 2005·The New England Journal of Medicine·Christoph WannerUNKNOWN German Diabetes and Dialysis Study Investigators
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Andrew J Krentz
Jun 15, 2006·The Journal of Nervous and Mental Disease·Julie KreyenbuhlLisa B Dixon
May 12, 2011·Journal of Cardiovascular Pharmacology·Nga N TaYan Huang
Oct 11, 2007·Diabetes, Obesity & Metabolism·Andrew J KrentzChristopher D Byrne
Mar 8, 2008·International Journal of Clinical Practice·G A Thomson
Mar 30, 2007·The American Journal of Pathology·Faikah GuelerHermann Haller
Apr 7, 2005·Current Medical Research and Opinion·B Vergès
Jun 29, 2007·Kidney International·V S StelF W Dekker
Jan 15, 2008·Journal of Diabetes and Its Complications·Ludovica PiconiAntonio Ceriello
Mar 6, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·E BruckertE Eschwege
Aug 2, 2005·Atherosclerosis. Supplements·Charles A Reasner
Jan 31, 2006·Diabetes Care·Merlin C ThomasPer-Henrik Groop
Oct 3, 2008·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Monique A M Jacobs-van der BruggenCaroline A Baan
Aug 30, 2005·The Journal of Biological Chemistry·William R LagorGene C Ness
Jan 13, 2006·Current Opinion in Lipidology·Khan PohlelNanette K Wenger
Dec 2, 2005·Treatments in Endocrinology·Craig S StumpJames R Sowers
Feb 24, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Anna C Calkin, Terri J Allen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.